NCT03421574已完成不适用
Phase I Trial of MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Major Depression
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Incidence of Treatment-Emergent Adverse Events
研究概览
简要总结
The proposed study is to evaluate the safety and initial efficacy of MRgFUS for patients with treatment-refractory Major Depression. This study is designed as a prospective, single arm, nonrandomized study. Assessments will be made before and after MRgFUS for adverse events related to treatment, for clinical symptom relief, and quality of life (QoL). The target in the brain chosen for ablation will be the anterior limb of the internal capsule (i.e 'capsulotomy').
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women ≥20 and ≤80 years of age.
- •Patients who are able and willing to give consent and physically and practically able to attend study visits, as determined by both study Psychiatrist and the surgeon.
- •DSM-V diagnosis of major depressive episode, as a component of an Axis I disorder, such as Major Depressive Disorder, Bipolar Disorder, Anxiety Disorder, Eating Disorder, Substance Abuse/Dependence Disorder ,or Personality Disorder
- •At least 5-year illness history of the primary disorder and at least 6 months since the onset of the first episode of major depression.
- •A minimum score of 20 on the Hamilton Depression Rating Scale (HAMD) when depressed (patients with bipolar disorder may be rapid cycling, but have to have at least 2 weeks of major depression at the time the HAMD is conducted)
- •Medication-refractoriness as determined by an adequate dose and duration of standard psychiatric treatments (including psychotherapy and/or pharmacology) as determined by two psychiatrists associated with the study. Including specifically:
- •Failed to respond or tolerate adequate trial of three or more medications accepted as first line in the treatment of depression
- •Failed to respond or tolerate augmentation with or combination,of at least 2 medications known to be first line treatments for depression
- •An adequate trial of cognitive behavioural therapy or other evidence-supported psychotherapy, delivered by a therapist experienced in treating depression
- •Able to communicate sensations during the ExAblate MRgFUS treatment
- •A consistent dose of any and all medications in the 30 days prior to study entry.
- •Women of childbearing potential must agree to use a contraception method throughout the study.
排除标准
- •Patients with unstable cardiac status [e.g. Unstable angina pectoris on medication, Patients with documented myocardial infarction within six months, Congestive heart failure requiring medication (other than diuretic), Patients on anti-arrhythmic drugs, Severe hypertension (diastolic BP > 100 on medication)]
- •Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
- •Severely impaired renal function (estimated glomerular filtration rate < 30ml/min/1.73 m2) or receiving dialysis
- •Laboratory biochemical evidence of abnormal bleeding and/or coagulopathy, including risk factors for intraoperative or postoperative bleeding (platelet count less than 100,000 per cubic millimeter or abnormal INR)
- •Cerebrovascular disease (e.g. CVA within 6 months) or history of intracranial hemorrhage
- •Untreated, uncontrolled sleep apnea
- •Receiving anticoagulant (e.g. warfarin) or antiplatelet (e.g. aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g. Avastin) within one month of focused ultrasound procedure
- •Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment
- •Are participating or have participated in another clinical trial in the last 30 days
- •Patients unable to communicate with the investigator and staff.
- •Presence of significant cognitive impairment
- •Presence of psychosis on clinical evaluation.
- •Patients with brain tumors already known or revealed on pretreatment MRI
- •Currently pregnant (as determined by history and serum HCG) or lactating.
结局指标
主要结局
Incidence of Treatment-Emergent Adverse Events
时间窗: 1 year
Safety of the ExAblate transcranial treatment will be determined by an evaluation of the incidence and severity of procedure related complications from the treatment day visit through the 12-month post-treatment time point. All events that are not procedure related will also be captured and recorded.
次要结局
- Clinical efficacy will be measured using the Hamilton Rating Scale for Depression (HAMD)(1 year)
- Clinical efficacy will be measured using the Beck Depression Inventory (BDI)(1 year)
- Quality of Life will be measured using the Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ)(1 year)
- Clinical efficacy will be measured using the Montgomery Asberg Depression Rating Scale (MADRS)(1 year)
- Clinical efficacy will be measured using the Columbia-Suicide Severity Rating Scale (C-SSRS)(1 year)
研究者
Dr. Nir Lipsman
Princiapl Investigator
Sunnybrook Health Sciences Centre
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Trial of MR-guided Focused Ultrasound (MRgFUS) Bilateral Capsulotomy for the Treatment of Refractory Obsessive-compulsive Disorder (OCD)Obsessive-Compulsive DisorderNCT03156335Sunnybrook Health Sciences Centre12
进行中（未招募）
不适用
MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal NeuralgiaTrigeminal NeuralgiaNCT04579692University of Maryland, Baltimore10
招募中
不适用
MRgFUS Pallidotomy for the Treatment of Task Specific Focal Hand Dystonia (TSFD)Task-Specific Focal DystoniaNCT06367608University of Maryland, Baltimore10
已完成
不适用
MR Guided Focused Ultrasound Surgery in the Treatment of Pain From Bone Tumors w/ the ExAblate 2000 Strappable SystemBone MetastasesNCT03547557InSightec10
终止
3 期
MR Guided Focused Ultrasound Surgery in the Treatment of Breast FibroadenomasBreast FibroadenomaNCT00147108InSightec102